Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Walvax Biotechnology Co., Ltd.
  6. Summary
    300142   CNE100000WN2

WALVAX BIOTECHNOLOGY CO., LTD.

(300142)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
68.25 68.8 65.06 64.41 65.88 Last
74361110 58179630 44144830 28832480 24644290 Volume
+0.96% +0.81% -5.44% -1.00% +2.28% Change
Estimated financial data (e)
Sales 2021 4 613 M 723 M 723 M
Net income 2021 1 399 M 219 M 219 M
Net Debt 2021 - - -
P/E ratio 2021 74,0x
Yield 2021 0,24%
Sales 2022 6 429 M 1 008 M 1 008 M
Net income 2022 1 916 M 300 M 300 M
Net Debt 2022 - - -
P/E ratio 2022 54,0x
Yield 2022 0,33%
Capitalization 105 B 16 440 M 16 441 M
Capi. / Sales 2021 22,7x
Capi. / Sales 2022 16,3x
Nbr of Employees 1 237
Free-Float 27,8%
More Financials
Company
Walvax Biotechnology Co. specialises in the research, development, manufacturing and marketing of human vaccines. Products include vaccines against haemophilus influenzae, meningitis, septicaemia, meningococcal disease, etc. 
Sector
Pharmaceuticals
Calendar
03/21Earnings Release
More about the company
Ratings of Walvax Biotechnology Co., Ltd.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about WALVAX BIOTECHNOLOGY CO., LTD.
11/28SoftBank, Others in Talks to Raise Up to $300 Million For Chinese Vaccine Maker Suzhou ..
MT
11/26SoftBank in investment talks with Chinese mRNA vaccine firm Abogen - sources
RE
10/28Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended Septe..
CI
10/25GENSCRIPT BIOTECH : Unit Signs Deal for License Application, Commercial Production of Vacc..
MT
10/16Guangdong Walvax Pharmaceuticals Technology Co., Ltd. announced that it has received CN..
CI
09/15INDONESIA IN TALKS WITH WHO TO BECOM : minister
RE
09/14Guangdong Walvax Pharmaceuticals Technology Co., Ltd. announced that it expects to rece..
CI
08/27WALVAX BIOTECHNOLOGY : Nepal allows late-stage trials for Chinese mRNA vaccine candidate -..
RE
08/27Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30..
CI
08/19WALVAX BIOTECHNOLOGY : China's mRNA vaccine technology firm Abogen raises over $700 millio..
RE
07/27Guangdong Walvax Pharmaceuticals Technology Co., Ltd. announced that it has received CN..
CI
06/10Beijing Walvax Innovation Biotechnology Co., Ltd. announced that it has received CNY 58..
CI
06/10Jiangsu Walvax Biotechnology Co., Ltd. announced that it has received CNY 30 million in..
CI
06/02China shares end lower on profit-booking of tech, healthcare stocks
RE
05/26Beijing Walvax Innovation Biotechnology Co., Ltd. announced that it expects to receive ..
CI
More news
News in other languages on WALVAX BIOTECHNOLOGY CO., LTD.
11/28SoftBank et d'autres acteurs sont en pourparlers pour lever jusqu'à 300 millions de dol..
10/25L'unité Biotech de Genscript signe un accord pour la demande de licence et la productio..
05/13Walvax Biotechnology Co., Ltd. annonce un dividende final en espèces sur les actions A ..
05/06MÄRKTE ASIEN/Tokio sehr fest - Chin. Impfstoffhersteller stürzen ab
05/06MÄRKTE ASIEN/Japan sehr fest - Konflikt mit China belastet Sydney
More news
Chart WALVAX BIOTECHNOLOGY CO., LTD.
Duration : Period :
Walvax Biotechnology Co., Ltd. Technical Analysis Chart | 300142 | CNE100000WN2 | MarketScreener
Technical analysis trends WALVAX BIOTECHNOLOGY CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 65,88 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Run Sheng Jiang President & Director
Hua Zhou Chief Financial Officer
Yun Chun Li Chairman
Ling Ling Tang Chairman-Supervisory Board
Chao Hong Na Independent Director
Sector and Competitors
1st jan.Capi. (M$)
WALVAX BIOTECHNOLOGY CO., LTD.70.85%16 440
CSL LIMITED5.12%95 233
WUXI BIOLOGICS (CAYMAN) INC.0.39%56 209
SAMSUNG BIOLOGICS CO.,LTD.8.96%50 311
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-6.27%32 892